首页> 外文期刊>Journal of thrombosis and haemostasis: JTH >Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: A proposed prediction score (DASH)
【24h】

Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: A proposed prediction score (DASH)

机译:预测先前有无因性静脉血栓栓塞的患者的疾病复发:建议的预测评分(DASH)

获取原文
获取原文并翻译 | 示例
       

摘要

Background: In patients with unprovoked venous thromboembolism (VTE), the optimal duration of anticoagulation is anchored on estimating the risk of disease recurrence. Objectives: We aimed to develop a score that could predict the recurrence risk following a first episode of unprovoked VTE, pooling individual patient data from seven prospective studies. Methods: One thousand eight hundred and eighteen cases with unprovoked VTE treated for at least 3months with a vitamin K antagonist were available for analysis. Optimism-corrected Cox regression coefficients were used to develop a recurrence score that was subsequently internally validated by bootstrap analysis. Results: Abnormal D-dimer after stopping anticoagulation, age <50years, male sex and VTE not associated with hormonal therapy (in women) were the main predictors of recurrence and were used to derive a prognostic recurrence score (DASH, D-dimer, Age, Sex, Hormonal therapy) showing a satisfactory predictive capability (ROC area=0.71). The annualized recurrence risk was 3.1% (95% confidence interval [CI], 2.3-3.9) for a score≤1, 6.4% (95% CI, 4.8-7.9) for a score=2 and 12.3% (95% CI, 9.9-14.7) for a score≥3. By considering at low recurrence risk those patients with a score≤1, life-long anticoagulation might be avoided in about half of patients with unprovoked VTE. Conclusions: The DASH prediction rule appears to predict recurrence risk in patients with a first unprovoked VTE and may be useful to decide whether anticoagulant therapy should be continued indefinitely or stopped after an initial treatment period of at least 3 months.
机译:背景:对于无缘无故的静脉血栓栓塞症(VTE)的患者,最佳抗凝持续时间取决于估计疾病复发的风险。目的:我们旨在收集可预测七项前瞻性研究中的个体患者数据的评分,该评分可预测无缘无故的VTE首次发作后的复发风险。方法:分析了1881例未经治疗的VTE至少3个月并接受维生素K拮抗剂治疗的患者。使用乐观校正的Cox回归系数来制定复发评分,随后通过自举分析对其进行内部验证。结果:停止抗凝治疗后D-二聚体异常,年龄<50岁,男性和与激素治疗无关的VTE(女性)是复发的主要预测指标,并用于得出预后复发评分(DASH,D-二聚体,年龄) ,性别,荷尔蒙疗法)显示出令人满意的预测能力(ROC面积= 0.71)。分数≤1的年复发风险为3.1%(95%置信区间[CI],2.3-3.9),分数= 2的年复发风险为6.4%(95%CI,4.8-7.9)和12.3%(95%CI, 9.9-14.7)得分≥3。通过考虑低复发风险的那些那些得分≤1的患者,大约一半的未经批准的VTE患者可以避免终生抗凝治疗。结论:DASH预测规则似乎可以预测初发VTE的患者的复发风险,并且对于决定是否应无限期继续抗凝治疗或在初始治疗期至少3个月后停止抗凝治疗可能有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号